Transverse myelitis in patients with antiphospholipid antibodies - The importance of early diagnosis and treatment

Y. Sherer, S. Hassin, Y. Shoenfeld, Y. Levy, A. Livneh, A. Ohry, P. Langevitz

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

Transverse myelitis (TM) is a rare manifestation of systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). No uniform therapeutic protocol exists for its treatment, and the prognosis is usually poor. Here we describe four patients having TM associated with antiphospholipid antibodies. Treatment measures and delay in diagnosis between symptom onset and the initiation of treatment varied between patients, but the earlier the diagnosis and the more aggressive the treatment the better was the patient's outcome. Based on these cases and on a literature review we suggest that early aggressive treatment (usually with pulses of methylprednisolone and cyclophosphamide) might improve the prognosis of patients with TM associated with antiphospholipid antibodies.

Original languageEnglish
Pages (from-to)207-210
Number of pages4
JournalClinical Rheumatology
Volume21
Issue number3
DOIs
StatePublished - 30 Jul 2002
Externally publishedYes

Keywords

  • Anticardiolipin antibody
  • Antiphospholipid antibody
  • Cyclophosphamide
  • Steroids
  • Transverse myelitis

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Transverse myelitis in patients with antiphospholipid antibodies - The importance of early diagnosis and treatment'. Together they form a unique fingerprint.

Cite this